Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multiple-dose safety, tolerability, and pharmacokinetics study of LY3045697 in healthy subjects
NL-OMON38581Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- May 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Trial of LY3045697 in chronic kidney disease (CKD), sponsored by Eli Lilly and Company. Primary endpoint: Safety and tolerability of LY3045697. Started May 2013; status: active, not recruiting.
02
Drugs
LY3045697
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NL-OMON38581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38581.